for its treatment. γ-Aminobutyric acid (GABA) transporters 1 and 4 (mGAT1 and mGAT4) have been increasingly recognized as promising drug targets for neuropathic pain (NP) associated with imbalances in inhibitory neurotransmission. In this context, we designed and synthesized new functionalized amino acids as inhibitors of GABA uptake and assessed their activities toward all four mouse GAT subtypes
对药物治疗的神经性疼痛抵抗鼓励研究人员开发有效的治疗方法。γ-
氨基
丁酸 (
GABA) 转运蛋白 1 和 4(mGAT1 和 mGAT4)越来越被认为是与抑制性神经传递失衡相关的神经性疼痛 (NP) 的有希望的药物靶点。在这种情况下,我们设计并合成了新的功能化
氨基酸作为
GABA 摄取的
抑制剂,并评估了它们对所有四种小鼠 GAT 亚型 (mGAT1-4) 的活性。根据所获得的结果,化合物2个RS,4个RS - 39C(
PIC 50(mGAT4)= 5.36),50A(
PIC 50(MGAT2)= 5.43),和56A(具有有利于 mGAT4 的中等亚型选择性,
PIC 50 (mGAT4) = 5.04)特别令人感兴趣,因此评估了它们的细胞毒性和肝毒性作用。在一组体内实验中,化合物50a和56a在三种 NP 啮齿动物模型中均显示出镇痛作用,即化疗诱导的神经病理性疼痛模型(
奥沙利铂模型和
紫杉醇模